Skip to main content

Advertisement

Table 3 Summary of the meta-analysis findings of the differences of clinical and laboratory parameters between the DR4+ and DR4- in RA patients

From: Meta-analysis of the association of HLA-DRB1 with rheumatoid arthritis in Chinese populations

Polymorphisms Eligible studies Baseline comparability Case (N or n/N) DR4+ Control (N or n/N) DR4- WMD/OR (95% CI) p–value Heterogeneity test Effect model
ESR 10 Yes 590 762 0.26 (0.15, 0.37) <0.00001 p=0.16, I [2]=31% Fixed
  Northerner 7 Yes 458 562 0.22 [0.09, 0.35] 0.0007 p=0.13, I [2]=40%  
  Southerner 3 Yes 132 200 0.39 [0.17, 0.61] 0.0006 p=0.16, I [2]=31%  
CRP 6 Yes 325 436 0.26 [0.12, 0.41] 0.0005 p=0.11, I [2]=44% Fixed
RF 4 Yes 139 246 0.44 [0.23, 0.65] <0.00001 p=0.42, I [2]=0% Fixed
Anti-CCP 2 Yes 52 123 0.58 [0.24, 0.91] 0.0007 p=0.28, I [2]=15% Fixed
Duration of morning stiffness 5 Yes 228 337 0.23 [-0.01, 0.48] 0.06 p=0.11, I [2]=47% Fixed
Number of swollen joints 7 Yes 414 527 0.13 [-0.00, 0.26] 0.05 p=0.29, I [2]=18% Fixed
Number of joint tenderness 6 Yes 368 437 0.08 [-0.06, 0.23] 0.25 p=0.67, I [2]=0% Fixed
X-ray phases 8 Yes 137/368* 142/365* 0.93 (0.66–1.29)’ 0.65 p=0.1, I [2]=42% Fixed
  I ~ II 3 Yes 44/108* 63/135* 0.47 (0.26–0.87)’ 0.02 p=0.75, I [2]=0%  
  III ~ IV 5 Yes 93/260* 79/230* 1.27 (0.84–1.92)’ 0.25 p=0.26, I [2]=25%  
Joint function 8 Yes 93/260* 79/230* 0.89 (0.65–1.23)’ 0.6 p=0.02, I [2]=58% Random
  I ~ II 3 Yes 124/364* 182/463* 0.59 (0.35–1)’ 0.05 p=0.51, I [2]=0%  
  III ~ IV 5 Yes 56/149* 96/170* 1.14 (0.76–1.69)’ 0.88 p=0.02, I [2]=65%  
  1. 'n’ stands for number of positive events, 'N’ stands for number of total events.
  2. * n/N.
  3. 'OR (95%CI).